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Abstract
Irritable bowel syndrome (IBS) is a common condition with a complex and largely unknown etiology. There is no
cure, and treatment options are mainly directed to the amelioration of symptoms. IBS causes reduced quality of life
and poses considerable repercussions on health and socioeconomic systems. There is a heritable component in IBS,
and genetic research is a valuable tool for the identification of causative pathways, which will provide important insight
into the pathophysiology. However, although some gene-hunting efforts have been conducted and a few risk genes
proposed, IBS genetic research is lagging behind compared to other complex diseases. In this mini-review, we briefly
summarize existing genetic studies, discuss the main challenges in IBS genetic research, and propose strategies to
overcome these challenges for IBS gene discovery.
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Irritable bowel syndrome prevalence
Irritable bowel syndrome (IBS) is the most commonly di-
agnosed functional gastrointestinal disorder (FGID) with a
worldwide prevalence of 10–20 %, predominantly among
women [1]. Its clinical appearance varies but is usually
characterized by recurrent abdominal pain or discomfort
accompanied by changes in bowel habits and diarrhea
(IBS-D), constipation (IBS-C), or both (mixed, IBS-M). In
the absence of reliable biomarkers or specific laboratory
tests, consensus criteria towards a positive diagnosis have
been developed: the symptom-based Rome III criteria [2].
Due to a complex and not fully elucidated pathophysi-
ology, there is no cure, and available treatment options
can only be directed to amelioration of symptoms in a
trial-and-error approach based on patients’ individual
symptomatology. Comorbidity with other FGIDs as well
as psychological conditions such as depression and anxiety
is observed, as well as certain non-gastrointestinal non-
psychological comorbidities including fibromyalgia,
chronic fatigue syndrome, and chronic pelvic pain [3]. IBS
negatively affects quality of life, which reflects in increased
work and school absenteeism, decreased work productiv-
ity, and higher utilization of the health care system, with
considerable repercussions on health and socioeconomic
systems [3, 4].
IBS pathophysiology
Structural abnormalities, tissue damage, or other organic
explanations are typically absent in IBS. Therefore, this
condition is traditionally classified as a functional gastro-
intestinal disorder. Due to significant associations with
anxiety, depression, and other psychiatric conditions,
IBS has often been considered to be a psychosomatic
disorder. However, more recent research has contributed
to the elucidation of several mechanisms that may play
important roles in IBS [5–7], see Fig. 1. We now under-
stand that mucosal immune activation, inflammatory
cells, and elevated inflammatory markers may be present
in IBS, at least in a subset of patients. Prior gastroenter-
itis (post-infectious IBS; PI-IBS), described effects of
antibiotics and probiotics on IBS symptoms, and the
observation of different gut microbiota profiles in pa-
tients and controls all speak for an important role of gut
flora in IBS [7]. In addition, diet is recognized in some
patients as an important trigger of gut symptoms, and
dietary therapeutic approaches have been recently devel-
oped, such as the low-FODMAP diet where poorly
absorbed and rapidly fermentable carbohydrates are
avoided [8]. Visceral hypersensitivity and altered pain
perception also appear to be important features of IBS,
as demonstrated in rectal sensitivity experiments. To-
gether with the observation of abnormal gut motility
and alterations in enteroendocrine and neuropeptide
systems in relation to the enteric and central nervous
system as well as gut microbiota, perturbations in the
* Correspondence: mauro.damato@osakidetza.eus
2Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden
3BioCruces Health Research Institute and Ikerbasque, Basque Foundation for
Science, Bilbao, Spain
Full list of author information is available at the end of the article
© 2016 Henström and D’Amato. Open Access This article is distributed under the terms of the Creative Commons Attribution
4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made.
Henström and D’Amato Molecular and Cellular Pediatrics  (2016) 3:7 
DOI 10.1186/s40348-016-0038-6
gut-brain axis and its bidirectional communication have
been proposed among the central mechanisms in IBS
pathophysiology [5–7]. Other specific factors may instead
be important only for specific subgroups of IBS patients,
such as altered bile acid synthesis in IBS-D [5, 9].
The genetic architecture of IBS
A heritable component of IBS has been demonstrated in
twin and family studies, although heritability estimates
have varied between 0 and 57 % [10]. Recently, however, a
Swedish nationwide survey including more than 50,000
cases showed increased IBS risk among first-, second- and
third-degree relatives, clearly indicating that a genetic
component exists [11]. Evidence is now accumulating that
genetic risk in IBS spans from complex polygenic condi-
tions with combinations of common variants, to cases
with rare single gene abnormalities [12]. For the majority
of IBS patients, the genetic background will be constituted
by a large set of common genetic variants, each contribut-
ing a small risk effect. At the same time, there may be
subsets of patients where highly penetrant genetic vari-
ability in individual genes accounts for most of the pheno-
type. A good example of this phenomenon recently came
from a study at the Mayo Clinic in collaboration with our
group [13]: sequencing of the SCN5A gene in 584 IBS
patients and 1380 asymptomatic controls identified func-
tionally deleterious mutations in 2.2 % of IBS cases but
none among controls. The SCN5A gene encodes the
NaV1.5 ion channel responsible for the pacemaker func-
tion of the heart but is also present on interstitial cells of
cajal, the ‘pacemaker’ cells of the gut. Most of the muta-
tions identified were loss-of-function and carriers most
often constipation-predominant. Of note, a severe IBS-C
case with a highly penetrating SCN5A loss-of-function
mutation could be successfully treated with mexiletine, a
drug known to restore NaV1.5 channel function. In
addition, also common SCN5A single nucleotide polymor-
phisms (SNPs) were found to affect IBS risk in our pilot
genome-wide association study (GWAS) of ~5000 sub-
jects (described further down), as well as in four inde-
pendent case-control cohorts from Sweden, Italy, Greece,
and the USA. These findings hence strengthen the hy-
pothesis that both rare mutations and common variants
may be implicated in IBS. However, overall, gene-hunting
efforts in IBS have so far been scarce [12], and large-scale
efforts remain to be carried out. Recognizing that IBS
spans from complex polygenic conditions to rare single-
gene forms, we need to adopt different strategies to iden-
tify these genetic factors.
The challenge in finding IBS-risk genes: past and
future perspectives
More than 60 candidate genes have been studied for
IBS, including genes involved in serotonin synthesis and
reuptake, mucosal immune activation and inflammation,
neuropeptide signaling, nociception, bile acid synthesis,
and intestinal secretion. These genetic findings have
been reviewed and discussed thoroughly before, and a
selection of genes showing best evidence of association
to IBS is reported in Table 1 [10, 12]. However, all of
these studies are candidate-gene case-control studies
conducted in relatively small sample sets. Many of the
identified associations have not been successfully repli-
cated in independent studies, and although p values have
been nominally significant, none of the findings are close
to sustain the correction for a GWA study. Therefore,
Fig. 1 Factors proposed to be involved in the complex pathophysiology of irritable bowel syndrome. CNS central nervous system, ENS enteric
nervous system. Prominent, proposed IBS-risk genes from Table 1 are also reported, by positioning them based on the (most likely) mechanistic
involvement in the mentioned pathways
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IBS-risk genes thus far proposed mostly still represent
non-validated hits rather than true predisposing factors,
and we have very few convincing IBS-risk genes identified
so far. One exception may be the TNFSF15 gene, which
was convincingly associated in our original study [14] and
then successfully replicated in independent cohorts
[15–17]. In the original study, we hypothesized that genes
involved in immune responses and host-microbe interac-
tions may also contribute to IBS susceptibility, since these
are mechanisms suggested to be involved in IBS patho-
physiology [5, 7]. Therefore, we tested the association of
polymorphisms (SNPs) from 30 known Crohn’s disease
risk loci on IBS risk in two case-control studies from
Sweden and the USA (total n = 1992). The G allele (risk
allele for Crohn’s) of rs426839 in TNFSF15 was signifi-
cantly associated with increased risk of IBS (p = 2.2e-05;
OR 1.37) and even more in IBS-C (p = 8.7e-07; OR 1.79).
This gene encodes the TL1A protein expressed in immune
cells, which promotes inflammatory response in the gut
mucosa. Carrying the risk allele is suggested to result in
higher TL1A expression and thereby stronger T cell acti-
vation and immune response. Hence, the association with
TNFS15 indicates that inflammatory response may be an
important mechanism also in IBS.
An alternative approach to the discovery of IBS rele-
vant genes is to study the endophenotypes, otherwise
called intermediate phenotypes of disease. These are
usually quantitative traits related to IBS, such as colonic
transit time and visceral sensitivity ratings. To focus on
biological observations instead of clinical entities for es-
tablishing, diagnosis was proposed already 50 years ago,
and this alternative strategy has been used successfully
for genetic studies in the psychiatric field where illnesses
often are, as IBS, complex and heterogeneous [18]. The
concept of endophenotypes is to use disease-associated
phenotypes in an attempt to reduce the complexity and
Table 1 Prioritized IBS-risk genes based on existing published statistical evidence
Gene Chr location Gene name Gene function Gene region Phenotype Key reference
TNFSF15 9q32 Tumor necrosis factor
(ligand) superfamily,
member 15
Codes for TNF-like ligand 1A (TL1A),
which contributes to the modulation
of inflammatory responses.
Intron IBS, IBS-C [14]
Intron and upstream IBS-D [15]
Intron IBS-A [16]
Intron IBS, IBS-C [17]
TLR9 3p21.3 Toll-like receptor 9 A Toll-like receptor that activate the
immune system through recognition
of specific patterns on microorganisms.





A receptor for serotonin, a neurotransmitter in
the central nervous system and gastrointestinal
tract.
3′UTR IBS-D [28]
NPSR1 7p14.3 Neuropeptide S
receptor 1
Receptor for neuropeptide S, expressed in
brain and enteroendocrine cells, involved








5′ near gene and
beginning of gene
RAP [21]
KLB 4p14 Klotho beta Co-receptor of fibroblast growth factor 19
(FGFR4) on hepatocyte membrane, required
for suppression of bile acid synthesis in liver.
Coding polymorphism Colonic transit
in IBS-D
[9]
SCN5A 3p21 Sodium channel,
voltage gated, type V
alpha subunit
Voltage-gated sodium channel (NaV1.5) in
pacemaker cells of the heart and interstitial
cells of cajal (ICC) cells of the gut important
for smooth muscle contraction.
Rare coding mutations
and signal of common
SNPs in middle of
gene
IBS, IBS-C [13]
CDC42 1p36.1 Cell division cycle 42 A small GTPase of the Rho-subfamily involved
in cell cycle regulation and possibly epithelial
barrier function through intestinal stem cell
differentiation and proliferation.
Intron IBS-C [16]




Belongs to a family of KDEL motif binding
receptors, mediating the retrograde transport
of proteins to the endoplasmatic reticulum.
Intron IBS [25]
Chr chromosomal location, IBS-D diarrhea-predominant IBS, IBS-C constipation-predominant IBS, IBS-A alternating IBS, PI-IBS post-infectious IBS, RAP recurrent
abdominal pain
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to increase chances of finding genes important to bio-
logical processes underlying disease etiology. For the case
of IBS, suitable traits to use for this approach include
bowel movement frequency, Bristol stool form scale (a
subjective measure of stool consistency, related to colonic
transit time), pain and sensation ratings in response to
visceral stimuli, and others. Previous work from our group
has shown associations between polymorphisms in the
neuropeptide S receptor gene (NPSR1) and colonic transit
time, as well as gastrointestinal (GI) sensory ratings, such
as gas, pain, and urgency [19]. The NPSR1 protein is a
receptor for neuropeptide S, a neuropeptide involved in
anxiety, response to stress and fear, inflammation, and
nociception. Neuropeptides act in the brain-gut axis and
have been implicated in IBS before [2, 6]. We also showed
that the neuropeptide S (NPS)-NPSR1 system can induce
the expression of other neuropeptides in vitro [19, 20].
Hence, this gene was a plausible candidate to investigate
also for its potential genetic associations with abdominal
pain. In the Swedish BAMSE birth cohort, we performed
a candidate-gene study in relation to recurrent abdominal
pain (RAP) [21], which occurs frequently among children
and is one of the cardinal symptoms of FGIDs. The mech-
anisms of visceral pain and RAP are not fully understood,
a heritable component has been demonstrated, and a few
candidate genes proposed. We observed association with
RAP at 7/24 tested SNPs, with the strongest signal in
correspondence of a putative regulatory region upstream
NPSR1 where they may exert their genetic effects through
the modulation of gene expression.
Overall, IBS poses some major challenges, and it appears
that in order to overcome these and be able to identify
true unequivocal risk genes and variants, we need to
implement larger scale analyses. Genetic-risk genes and
variants have been successfully identified and replicated in
a plethora of complex diseases using the powerful and
hypothesis-free approach of GWAS studies and their
meta-analyses (see the NHGRI-EBI GWAS Catalog;
www.ebi.ac.uk/gwas) [22]. For instance in the GI field, a
recent study reported the identification of 38 additional
susceptibility loci for inflammatory bowel disease (IBD),
bringing the total tally of confirmed IBD risk loci to
200 [23]. On the contrary, IBS genetics is very much
lagging behind, and no similar GWAS effort had been
attempted before our Screening-Across Life Span Twin
(SALT) study (see below).
GWA studies are powerful approaches to discovering
genetic risk loci in complex diseases [24], though this has
never even been attempted in IBS. In order to reach the
statistical power necessary to detect meaningful associ-
ation, very large sample size is required. Unfortunately,
this is currently unfeasible in the IBS community, as the
number and size of well-characterized cohorts around the
world is still surprisingly slim. In fact, only a portion of
individuals suffering from IBS according to the Rome III
criteria seek medical attention for their symptoms, with
numbers reported ranging from 10 to 70 % [1]. In order
to reach more individuals, we propose to shift approach
and instead make use of general population samples for
discovery purposes in IBS genetics. Large biobanks and
general population cohorts offer a great opportunity to
perform genetic epidemiological association studies with
considerably larger sample sizes. When available, Rome
questionnaire data may be used to identify IBS cases and
asymptomatic controls in these large study populations. In
addition, genotype data may also be linked to phenotype
in these studies using the International Classification of
Diseases (ICD codes) and electronic medical records
(EMR). By shifting to a general population approach for
the discovery phase, we gain considerable sample size and
improve in the definition of controls, as they are co-
sampled with the cases and classified with the very same
investigative tools (for example questionnaires). However,
once IBS-risk genes and variants have been discovered,
validation of results should be performed by replication
and targeted analyses in case-control cohorts from gastro
clinics with well-characterized IBS patients and healthy
controls. Furthermore, investigating rare variants/muta-
tions in IBS, next-generation sequencing in selected cases
and controls will also be necessary.
Our group recently conducted the very first pilot
GWAS of IBS [25]. In this study, Rome II criteria from
questionnaires were used to identify 534 IBS cases and
4932 asymptomatic controls from the SALT study of the
Swedish Twin Registry. A GWAS was performed and top
regions replicated in six independent case-control studies
with patients and controls recruited from European and
US clinics. Confirmatory, one of the loci (harboring the
KDELR2 gene) was successfully replicated in all these
samples (total sample size of 8977) with consistent effect
of association. Even though sample size was still too
small to reach genome-wide significance, this study
corroborated our hypothesis that general population-
based cohorts with associated genetic and epidemio-
logical/healthcare data provide excellent opportunities
to study the genetic architecture of IBS and related
GI symptoms.
Overall, the ultimate value of genetic research in IBS
is to identify key physiological mechanisms, which will
help us understand its pathophysiology. These findings
will help improve IBS diagnosis and classification and
therefore impact therapeutic strategies and personal-
ized treatments.
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